Immunome, Inc.
IMNMNASDAQHealthcare● Active
$18.42
$-0.16(-0.86%)
Market Cap$1.8B
P/E Ratio—
52W High$27.65
52W Low$7.96
Immunome, Inc. (IMNM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IMNM · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.48
Est. -$0.60 · +20.0%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
IMNM reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.36
Rev. $5.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.36
Rev. Est.$5.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$0.54 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 12, 2026 | -$0.60 | -$0.48 | +20.0% | — | $0.00B | — |
| ▼ Q1 FY2026 | Mar 3, 2026 | -$0.59 | -$0.75 | -27.1% | — | $0.00B | — |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.57 | -$0.65 | -14.0% | — | $0.00B | — |
| ▲ Q3 FY2025 | Aug 6, 2025 | -$0.52 | -$0.50 | +3.9% | $0.00B | $0.00B | +381.8% |
| ▲ Q2 FY2025 | May 12, 2025 | -$0.66 | -$0.52 | +21.2% | $0.00B | $0.00B | +540.1% |
| ▼ Q1 FY2025 | Mar 19, 2025 | -$0.68 | -$0.84 | -23.5% | $0.00B | $0.00B | -13.0% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$0.60 | -$0.78 | -30.0% | $0.00B | $0.00B | -7.8% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$0.54
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Beat
EPS Actual
-$0.48
EPS Est.
-$0.60
EPS Surpr.
+20.0%
Revenue
—
Q1 FY2026
Mar 3, 2026Miss
EPS Actual
-$0.75
EPS Est.
-$0.59
EPS Surpr.
-27.1%
Revenue
—
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.65
EPS Est.
-$0.57
EPS Surpr.
-14.0%
Revenue
—
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
-$0.50
EPS Est.
-$0.52
EPS Surpr.
+3.9%
Revenue
$0.00B
Q2 FY2025
May 12, 2025Beat
EPS Actual
-$0.52
EPS Est.
-$0.66
EPS Surpr.
+21.2%
Revenue
$0.00B
Q1 FY2025
Mar 19, 2025Miss
EPS Actual
-$0.84
EPS Est.
-$0.68
EPS Surpr.
-23.5%
Revenue
$0.00B
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$0.78
EPS Est.
-$0.60
EPS Surpr.
-30.0%
Revenue
$0.00B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.55 | $-0.55 | $-0.55 | 3 |
| Q3 FY2027 | $-0.50 | $-0.50 | $-0.50 | 4 |
| Q2 FY2027 | $-0.53 | $-0.53 | $-0.53 | 3 |
| Q1 FY2027 | $-0.59 | $-0.59 | $-0.59 | 3 |
| Q4 FY2026 | $-0.59 | $-0.59 | $-0.59 | 7 |
| Q3 FY2026 | $-0.59 | $-0.56 | $-0.54 | 9 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 4 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 4 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 7 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +20.0% | $23.00 | $22.69 | -1.35% |
| ▼ Q1 FY2026 | Mar 3, 2026 | -27.1% | $22.21 | $21.54 | -3.02% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -14.0% | $15.35 | $15.50 | +0.98% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +3.9% | $10.85 | $10.46 | -3.59% |
| ▲ Q2 FY2025 | May 12, 2025 | +21.2% | $7.46 | $7.94 | +6.43% |
| ▼ Q1 FY2025 | Mar 19, 2025 | -23.5% | $8.36 | $8.57 | +2.51% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -30.0% | $12.49 | $11.59 | -7.21% |
| ▼ Q3 FY2024 | Aug 12, 2024 | -28.9% | $12.92 | $12.64 | -2.17% |
Q2 FY2026-1.35%
Report Date
May 12, 2026
EPS Beat/Miss
+20.0%
Price Before
$23.00
Price After
$22.69
Q1 FY2026-3.02%
Report Date
Mar 3, 2026
EPS Beat/Miss
-27.1%
Price Before
$22.21
Price After
$21.54
Q4 FY2025+0.98%
Report Date
Nov 6, 2025
EPS Beat/Miss
-14.0%
Price Before
$15.35
Price After
$15.50
Q3 FY2025-3.59%
Report Date
Aug 6, 2025
EPS Beat/Miss
+3.9%
Price Before
$10.85
Price After
$10.46
Q2 FY2025+6.43%
Report Date
May 12, 2025
EPS Beat/Miss
+21.2%
Price Before
$7.46
Price After
$7.94
Q1 FY2025+2.51%
Report Date
Mar 19, 2025
EPS Beat/Miss
-23.5%
Price Before
$8.36
Price After
$8.57
Q4 FY2024-7.21%
Report Date
Nov 13, 2024
EPS Beat/Miss
-30.0%
Price Before
$12.49
Price After
$11.59
Q3 FY2024-2.17%
Report Date
Aug 12, 2024
EPS Beat/Miss
-28.9%
Price Before
$12.92
Price After
$12.64
Avg Beat Reaction+0.50%
Avg Miss Reaction-1.78%
Beat Rate3 / 8 quarters
Largest Move-7.21% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IMNM ends December
Immunome, Inc. (IMNM) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.48 — beating the analyst consensus of $-0.60 by +20.0%. The next IMNM earnings date is expected around September 1, 2026.
Each quarter, investors track IMNM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IMNM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IMNM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IMNM earnings · 5 questionsImmunome, Inc.'s next earnings report is expected around September 1, 2026. IMNM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IMNM historically reports after market close (AMC).
IMNM earnings datewhen is IMNM earningsIMNM next earnings datewhen does IMNM report earningsIMNM earnings calendar
▸ Source: FMP · Immunome, Inc. SEC filings · US GAAP · Immunome, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026